Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors

NCT06425926 is registered in ClinicalTrials.gov with Georgiamune Inc as lead sponsor.

NCT NCT06425926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06425926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors
Lead sponsor
Georgiamune Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 9, 2024
Completion date
November 30, 2027
Enrollment
117 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iv, solid tumor